Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PROGENICS PHARMACEUTICALS INC | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 6, 2016
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
000-23143 |
13-3379479 | |
|
One World Trade Center, 47th Floor, New York, New York |
10007 | ||
|
(Address of principal executive offices) |
(Zip Code) | ||
|
Registrant’s telephone number, including area code (646) 975-2500 |
|||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 7.01. |
Regulation FD Disclosure. |
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets.
A copy of the press release announcing the launch is furnished as Exhibit 99.1 to this report.
The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or as otherwise subject to liability of that section, nor shall such information be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act.
|
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated September 6, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROGENICS PHARMACEUTICALS, INC. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Patrick Fabbio |
|
|
|
|
Patrick Fabbio |
|
| Senior Vice President and Chief Financial Officer | |||
|
|
|
(Principal Financial and Accounting Officer) |
|
Date: September 6, 2016